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mosis. In our experience, roughly 10% of
patients will have low volume amylase-rich
fluid draining via the drains. Over 85% of these
low volume pancreatic fistulas will heal with
conservative management. While pancreatic
fistula has not disappeared as a postoperative
complication, it is certainly no longer the
dreaded and feared complication that it was
several decades ago. As additional experience
and data are gathered, perhaps one particular
technique of pancreatic reanastomosis will as-
sume priority.
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Budd-Chiari Syndrome" Shunt or Transplant?
ABSTRACT
Hemming, A. W., Langer, B., Greig, P., Taylor, B. R.
Adams, R. and Heathcote, J. (1996) Treatment of Budd-
Chiari syndrome with portosystemic shunt or liver
transplantation. The American Journal of Surgery; 171:
176-181.
Background: Budd-Chiari syndrome is an uncommon
disorder caused by obstruction to hepatic venous outflow,
causing varying degrees of hepatic injury depending on the
extent, severity, and acuity of the obstruction.
Patients and Methods: We reviewed the indications for
operative intervention and the results of treating 32
patients with Budd-Chiari syndrome seen at Toronto
Hospital between 1968 and 1995.
Results: Twenty-one patients underwent porto-systemic
shunt (PSS) and 7 patients underwent liver transplantation
(LT) as their initial operative management. Three patients
who initially had PSS subsequently required LT. Patients
with cirrhosis found on biopsy and preservation of
hepatocellular function were treated with PSS and showedHPB INTERNATIONAL 137
no difference in outcome when compared with patients
without cirrhosis (P=0.35). Patients who were treated by
PSS with retrohepatic vena caval compression, as shown by
high caval gradients had outcomes similar to those for
patients with low gradients (P=0.31). Using the Kaplan-
Meier method, 5-year survival of PSS patients was 57%.
Liver transplantation was used to manage patients with
hepatic decompensation, as well as patients with vena
caval occlusion or failed PSS. The 5-year Kaplan-Meier
survival for LT was 67%.
Conclusions: Both PSS and LT are effective options in the
management of Budd-Chiari syndrome. Portosystemic
shunt is the preferred initial approach even with cirrhosis
or retrohepatic caval compression as long as there is
preservation of liver function and a patent vena cava. Liver
transplantation should be used as primary therapy for
patients with irreversible hepatic decompensation or vena
caval occlusion, and it can be an effective salvage procedure
following failed PSS. (Am. J. Surg., 1996; 171,176-181).
Keywords: Portal hypertension, portacaval shunt, liver trans-
plant
PAPER DISCUSSION
Budd-Chiari syndrome (BCS) is no longer a rare
condition. Since publication of the initial de-
scription in 1842, over 2,000 cases have been
reported in the medical literature. During the
decade from 1981 to 1990, the number of
publications cited yearly in Index Medicus in-
creased from 32 to 64. The increase in incidence
is likely the result of increased awareness of
BCS, improvement in diagnostic methods, and
widespread use of thrombogenic agents such as
oral contraceptives.
During the past two decades, a substantial
number of reports of surgical treatment of BCS,
similar to the report of Hemming and collea-
gues, have been published. These reports have
consisted mainly of retrospective reviews of case
records of patients treated over a long period of
time by many surgeons performing a variety of
operations in the absence of a well-defined,
prospective plan of treatment. It is not possible
to perform valid statistical analyses, or base
valid conclusions, on such data. Moreover, as in
the report of Hemming et al., follow-up has been
inconsistent and has not been performed by the
surgeons who reported the results. Additionally,
comparison of different modalities of therapy
such as portosystemic shunt and liver trans-
plantation is not valid when the therapies being
compared were performed in different time
periods on patients with different stages of liver
disease.
Despite these shortcomings, Hemming and
associates have drawn some important conclu-
sions, as follows:
1. Portosystemic shunt (PSS) is the preferred
initial treatment in BCS without inferior vena
cava (IVC) obstruction as long as there is
preservation of liver function.
2. Cirrhosis in itself is not a contraindication to
PSS if hepatocellular function has been pre-
served.
3. Synthetic PSS materials should be avoided.
4. IVC compression with high caval gradients is
not a contraindication to PSS as long as the
IVC remains patent.
5. Following surgical therapy of BCS, patients
should be maintained on long-term anti-
coagulation.
6. Liver transplantaiton (LT) is indicated in (a)
patients with cirrhosis and poor hepatocellu-
lar function, (b) patients with failed PSS, and
(c) patients with fulminant hepatic failure due
to BCS.
7. LT is preferred over mesoatrial shunts for
patients with IVC obstruction and preserva-
tion of hepatocellular function.
We agree wholeheartedly with all of these
conclusions except the last one.
We have performed prospective studies of
BCS in 41 patients who were treated by portal
decompression and then underwent careful
follow-up by us that averaged more than six
years. Our results have been published [1-5]
and are summarized in Table I. In support of the
conclusions of Hemming and associates, we
have found side-to-side portacaval shunt to be
consistently effective in patients with BCS
caused by thrombosis of the hepatic veins. In138 HPB INTERNATIONAL
TABLE Long-term results of portal decompression operations in 41 patients with BCS treated by Orloff et al.
Hepatic vein IVC and hepatic vein occlusion
occlusion Mesoatrial Combined PCS
alone-PCS shunt and CAS
No. of patients 23 8 10
Onset to operation
_<17 weeks (%) 83 88 100
Mean No. of weeks 17 12 15
Range weeks 4 78 19 10 18
Follow-up (years)
Mean 10.0 6.0 6.2
Range 1.0- 22 2-13 10
Ascites (%) 0 63 0
Need for diuretics (%) 0 63 0
Abnormal liver function tests (%) 14 63 0
Portasystemic encephalopathy (%) 0 38 0
Employed or housekeeping (%) 95 25 90
Angiography results (%)
Patent shunt 91 37 100
Patent IVC 100 0 0
Occluded hepatic veins 100 100 100
Survival (%)
30-day 96% 100 100
Current 91% 38 100
our series of 23 patients with hepatic vein
occlusion alone, there has been only one
operative death (4%) and one long-term death.
The 22 survivors of operation have lived free of
ascites without diuretic therapy for from 1.0 to
22.0 years (mean 10.0 years). The shunt has
remained patent in all but two of the patients,
both of whom underwent successful reconstruc-
tion of the portocaval anastomosis with a H-
graft of autologous internal jugular vein. The
revised shunt has remained patent. Liver func-
tion has returned to normal in all but three
patients who had cirrhosis preoperatively. He-
patosplenomegaly has .disappeared, and there
has been no encephalopathy. Serial liver biop-
sies performed 1.0-22.0 years postoperatively
showed substantial reversal of the pathologic
lesions of BCS. Our experience demonstrates the
importance of performing side-to-side portaca-
val shunt early in the course of BCS in order to
reverse the liver damage and prevent extension
of thrombosis from the hepatic veins into the
inferior vena cava (IVC).
Splenorenal shunt and interposition mesoca-
val and portacaval shunts using synthetic grafts
are hemodynamically similar to side-to-side
portacaval shunt but, as Hemming and collea-
gues point out, are inferior operations in BCS
because of a high incidence of thrombosis and
occlusion. Interposition shunt using an auto-
logous internal jugular vein H-graft has been
used widely in France, and has produced results
similar to those of direct side-to-side portacaval
shunt.
Side-to-side portacaval shunt is contraindi-
cated when BCS is caused by thrombosis or
occlusion of the IVC. Under such circumstances,
a mesoatrial shunt with a synthetic graft has
been used with some short-term success. How-
ever, as pointed out by Hemming et al., there has
been a high incidence of thrombosis of synthetic
grafts. In our series of eight patients, thrombosisHPB INTERNATIONAL 139
of the mesoatrial shunt developed in five, and
the five-year survival rate was only 38%.
Similarly, others have reported thrombosis of
the mesoatrial shunt in 40-70% of patients, an
event that is often followed by death.
Because of dissatisfaction with the results of
mesoatrial shunt, we worked in the experimen-
tal laboratory to devise a shunting procedure
aimed at decompressing the hypertensive IVC
and shunting both the portal venous flow and
the entire inferior vena caval flow to the right
atrium [3]. The new operation, which consisted
of a combined side-to-side portacaval shunt and
a caval-atrial shunt through a Gore-Tex prosthe-
sis, was found to be very effective in relieving
BCS in rats, and has been successful in each of 10
patients with BCS due to IVC occlusion during
follow-up of 1.0-10 years (mean of 6.2 years).
The combined shunt results in a blood flow rate
in the synthetic graft that is much higher than in
the mesoatrial shunt. We believe the higher
blood flow rate accounts for the absence of
thrombosis. In our program, the combined shunt
operation has replaced mesoatrial shunt as the
preferred treatment for BCS caused by IVC
occlusion. We do not agree with the tentative
conclusion of Hemming and colleagues that LT
is the procedure of choice in patients with IVC
obstruction and preservation of hepatocellular
function.
Finally, it should be emphasized, as Hemming
and colleagues have done appropriately, that
PSS and LT are not competing procedures in the
treatment of BCS. PSS is the treatment of choice
when hepatocellular function is preserved and
patent veins are available for accomplishing the
shunt. LT is the treatment of choice when
hepatic decompensation has developed or when
PSS has failed. Both PSS and LT are effective in
the treatment of BCS, but they are used for
different stages of the disease.
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